PRME 4.35 Prime Medicine, Inc.
| Range: | 3.28-9.86 | Vol Avg: | 1335987 | Last Div: | 0 | Changes: | 0.06 |
| Beta: | 1.88 | Cap: | 0.44B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Oct 20 2022 | Empoloyees: | 234 | ||
| CUSIP: | 74168J101 | CIK: | 0001894562 | ISIN: | US74168J1016 | Country: | US |
| CEO: | Dr. Keith Michael Gottesdiener M.D., Ph.D. | Website: | https://www.primemedicine.com | ||||
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Stock Details
PRME 15
Prime Medicine assumed with a Buy at Jefferies
Maury Raycroft·Tue May 07 2024
Jefferies
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow